Filing Flows › Outlook Therapeutics (OTLK) › Q3 FY25
Outlook Therapeutics (OTLK) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Aug 14, 2025
Outlook Therapeutics (OTLK) reported revenue of $1.5M for the third quarter fiscal 2025 (Q3 FY25).
Outlook Therapeutics, Q3 FY25: revenue $1.5M, net loss $20.2M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | — | — |
| Operating profit | −$15.7M | — | — |
| Net earnings | −$20.2M | — | — |
| Operating cash flow | −$11.9M | — | — |
What changed
Revenue was $1.5M in Q3 FY25.
Gross margin was 70.8%. Operating costs exceeded revenue by $15.7M, an operating margin of -1046.2%. The quarter ended with a net loss of $20.2M.
Operating cash flow was −$11.9M. Non-cash charges added back $29K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items added $6.5M.
Questions
What was Outlook Therapeutics' revenue in the third quarter fiscal 2025?
Outlook Therapeutics (OTLK) reported revenue of $1.5M for the third quarter fiscal 2025 (Q3 FY25).